INOVAIT’s Pilot Fund now accepting applications for image-guided therapy projects

Oct 18, 2023
Raphael Ronen, Co-Executive Director of INOVAIT announces the INOVAIT Fall 2023 Pilot Fund Call for Applications at the Imaging the Future event in Vancouver, BC.

October 18, 2023 | Toronto, ON – INOVAIT, the pan-Canadian network for image-guided therapy (IGT), is now accepting applications to its Pilot Fund. The Pilot Fund is a reimbursement-based funding program to support collaborative research and development (R&D) projects in IGT that involve artificial intelligence technologies. Funding for this funding program was provided in part through the Government of Canada’s Strategic Innovation Fund (SIF).

The Pilot Fund aims to help initiate the most promising IGT projects to help improve patient outcomes and fuel economic development in Canada. This funding is designed for short-term (9–15 months) IGT commercialization-oriented R&D projects. Applying organizations can request between $100,000–$125,000 of non-dilutive investment, with INOVAIT contributing up to one-third of eligible supported costs in reimbursement funding.

“The possibilities offered by AI are infinite. That’s why the advances made by integrating Artificial Intelligence (AI) into Image Guided Therapies (IGTs) are invaluable to the patients and healthcare professionals who need it most. We are proud to support researchers and developers in pursuing more accurate diagnosis and treatment to improve health care for all Canadians.” – The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry.

The Pilot Fund will support industrial research, including activities related to the discovery of new knowledge that supports the development of new technology-driven products or services and large-scale technology demonstration. To date, the INOVAIT Pilot Fund has supported over 60 IGT projects by providing $7.2M for R&D projects across the country. Pilot Fund projects are selected based on their ability to demonstrate exceptional scientific, clinical, and technical merit, as well as enormous commercialization potential and economic impact.

“We are eager to see what Canadian image-guided therapy companies are developing and how we can best support the most promising technological ideas,” says Kullervo Hynynen, Co-Executive Director of INOVAIT and Vice President of Research and Innovation at Sunnybrook Research Institute. “By supporting the most compelling image-guided therapy projects, we are promoting a healthcare future that ensures Canadians will receive the best possible care.”

One-third of the contributions made by INOVAIT to a Pilot Fund project must be directed to Canadian-based Ultimate Recipients outside of Ontario.

To learn more about this funding opportunity, visit

Interested applicants can apply by registering with the INOVAIT Funding Portal at Applications can be submitted through the portal between October 18, 2023 and December 20, 2023. Full applications must be submitted by 11:59 pm Pacific Standard Time on December 20, 2023.

An online information session will be hosted on November 15, 2023 at 2:30 pm Eastern Standard Time. Interested applicants are encouraged to register for this webinar to learn more about this unique funding opportunity. Registration for the webinar can be found here: The live webinar will be hosted in English only. A recording will be made available after the webinar with both English and French captioning at


Established in 2020, INOVAIT invests strategically in collaborative partnerships that build upon Canada’s strength in digital innovation and health science research to create a critical mass of world-leading Image-guided therapy (IGT) companies. Hosted by the Sunnybrook Research Institute and supported by the Government of Canada’s Strategic Innovation Fund, the network brings together small, medium-sized, and large companies, research organizations, post-secondary institutions, and not-for-profit organizations. INOVAIT aims to build a truly integrated IGT ecosystem by fuelling continuous innovation that revolutionizes healthcare globally.

About Sunnybrook Research Institute

Sunnybrook Research Institute (SRI) is the research arm of Sunnybrook Health Sciences Centre, an internationally recognized academic health sciences centre fully affiliated with the University of Toronto. With well-established programs in basic and applied sciences which span across three scientific platforms and ten clinical programs, SRI is developing innovations in care for the more than 1.3 million patients the hospital cares for annually.

Share this on social media

Learn more about the network

Tenomix secures oversubscribed $2.1M, all-Canadian financing round to advance cancer staging

Tenomix secures oversubscribed $2.1M, all-Canadian financing round to advance cancer staging

Tenomix, an image-guided diagnostic company based out of Western University’s BioNext Medtech Incubator, recently celebrated a significant milestone with an oversubscribed all-Canadian $2.14M funding round. Established in 2021 by four alums of WORLDiscoveries’ Medical Innovation Fellowship program at Western University, Tenomix is transforming cancer staging, particularly in colorectal cancer, with its innovative approach.

PulseMedica is laser-focused on tackling vitreoretinal diseases

PulseMedica is laser-focused on tackling vitreoretinal diseases

The PulseMedica platform is a 3D image-guided therapy device that integrates powerful laser therapy, advanced medical imaging, and limitless machine learning (ML) for precision imaging and treatment of vitreoretinal disease. Vitreoretinal diseases exist within the clear gel (vitreous fluid) that fills the eye and retina at the back of the eye. PulseMedica’s device strives to automate the imaging and treatment process, enabling quick and precise disease targeting, thereby reducing the treatment time and reducing the risk of side effects and total time per patient, allowing for more patients to be treated each day.

Sonic Incytes is making liver screening more accessible 

Sonic Incytes is making liver screening more accessible 

Sonic Incytes, a Canadian artificial intelligence (AI)-assisted medical imaging company based out of Vancouver, British Columbia, is looking to change the way liver disease is screened and monitored globally. Their flagship, FDA cleared device, Velacur™, is revolutionizing the diagnosis and management of chronic liver disease. Their proprietary technology that grew into Velacur was originally developed by researchers at the University of British Columbia (UBC).